Addendum
Sacubitril/valsartan - Addendum to Commission A15-60
Report documents
-
Addendum
Sacubitril/valsartan - Addendum to Commission A15-60
Press releases
Sacubitril/valsartan in heart failure: differing added benefit
Effect modification: indication of minor added benefit with diabetes, indication of considerable added benefit without diabetes
Additional information
Federal Joint Committee (G-BA)
2016-06-16 A G-BA decision was published.
Project details
- Project no.
- A16-29
- Commission
- Commission awarded on 09.05.2016 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Heart and circulation
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Sacubitril/valsartan - Benefit assessment according to §35a Social Code Book V
Status: Commission completed